Surgery for spread pancreatic cancer? small trial halted early
NCT ID NCT06122480
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether surgically removing both the main pancreatic tumor and any limited spread to the liver or lungs could help people with pancreatic cancer live longer. Only 5 people enrolled before the trial was stopped early. Participants first received chemotherapy, then surgery if the cancer remained limited. The goal was to see if this aggressive approach improves survival compared to historical data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- surgery to remove the primary pancreatic tumor and any liver or lung metastases
- What this could lead to
- If successful, this approach could show that surgery plus chemotherapy improves survival for patients with limited spread of pancreatic cancer.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited. Surgery for metastatic pancreatic cancer carries significant risks and may not benefit everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pancreatic Cancer's inflammatory footprint be stopped?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- A sound wave that could expose hidden pancreatic cancer?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?